Blue Water Vaccines Shares Jump After Licensing Pact For Chlamydia Vaccine Candidate

  • Blue Water Vaccines Inc BWV has signed an exclusive, global license agreement for a live attenuated, oral Chlamydia vaccine candidate from The University of Texas Health San Antonio.
  • According to the CDC, Chlamydia is the most frequently reported bacterial STI in the U.S, with about 1.6 million new cases reported in 2020 alone.
  • Globally, the WHO estimates about 129 million new cases of chlamydia each year. This may be an underrepresentation given that many cases are asymptomatic and the low availability of diagnostic testing in low- and middle-income countries.
  • Currently, no vaccine is available to prevent chlamydia infection, and the primary treatment is through antibiotic regimens with the possibility of reinfection after antibiotics have treated the disease. 
  • If undetected or left untreated, chlamydia represents a significant cause of pelvic inflammatory disease and infertility in women.
  • Price Action: BWV shares are up 21% to $1.38 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareContractsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!